DexCom, Inc. (DXCM): DXCM RSI 5

TREND1 · 2017-04-06T14:11:52.4430000Z

DXCM RSI 5 www.stockcharts.com/c-sc/sc?s=DXCM&p=D&b=5&g=2&i=p21174799651&a=516886882&r=358&r=1491487807240

Play Episode

5min

Proactive - Interviews for investors

Data security: archTIS lands key licensing deal

archTIS Ltd CEO and Managing Director Daniel Lai talked with Proactive about a newly signed $390,000 licensing agreement with a major Japanese multinational. The deal builds on archTIS’s acquisition of Direktiv and its integration of advanced cybersecurity technology into its Trusted Data Integration platform. Lai explained that the licensing agreement enables the Japanese company—an asset services provider with operations valued at $12.5 billion—to introduce new data-centric security services into the Japanese market. “This is just another example of that occurring, which is really exciting for the company,” Lai said, referring to archTIS’s broader international expansion strategy. He noted that the company had always planned to replicate its success with the Australian Department of Defence and local defence industrial base in overseas markets, particularly those facing geopolitical pressures. Lai also highlighted progress in the US and Europe, where trials were recently completed with a large US department and NATO in the UK. Looking ahead, he remained “quietly optimistic” about meeting financial targets by June 30 and delivering further material updates to the market. He acknowledged market timing and election cycles as influencing deal flow, but said government and intelligence agency engagement continues to build momentum. Visit Proactive's YouTube channel for more interviews and updates. Don’t forget to like the video, subscribe, and turn on notifications for future content. #archTIS #Cybersecurity #DataSecurity #LicensingDeal #JapaneseMarket #QuadAlliance #TrustedDataIntegration #GlobalExpansion #DefenseTechnology #ProactiveInvestors

Proactive - Interviews for investors

Trevi Therapeutics advances cough treatment pipeline, eyes key clinical milestones

Trevi Therapeutics CEO Jennifer Good joined Steve Darling from Proactive to discuss the company’s progress in advancing its cough treatment pipeline using nalbuphine, a mixed agonist-antagonist opioid. Originally developed for acute indications, nalbuphine is now being repurposed due to its dual mechanism of action, working both peripherally in the lungs and centrally in the brainstem, offering a novel approach to treating chronic cough disorders. Trevi initially explored multiple indications, including skin conditions caused by severe itching and neurological cough. However, compelling clinical data led the company to focus on cough-related indications. Good explained, “We thought our drug was different because not only does it work peripherally in the lung, it works centrally at the brain, which mediates coughing and breathing.” The company is now targeting three key areas: interstitial lung diseases (including idiopathic pulmonary fibrosis, or IPF), refractory chronic cough (RCC), and other neurological cough conditions. Following promising Phase 2a results in RCC—an area where many previous drug candidates have failed—Trevi is preparing for a Phase 2b dose-ranging study. If successful, only one pivotal study may be required before regulatory filing. Good also highlighted Trevi’s strong financial position, noting that the company has sufficient cash runway to support its current studies through the second half of 2026, including further development in RCC and IPF. #proactiveinvestors #trevitherapeuticsinc #nasdaq #trvi #JenniferGood #Nalbuphine #ChronicCough #RefractoryCough #Phase2aResults #BiotechNews #PharmaPipeline #IPF #ClinicalTrials #CoughTreatment #NeurologicalDisorders #ProactiveInvestors

Proactive - Interviews for investors

St George Mining unveils major JORC resource

St George Mining Ltd executive chairman John Prineas talked with Proactive about the company's newly announced maiden JORC resource, which he says could be among the world’s most significant niobium and rare earth deposits. Prineas said the deposit features over 500 intercepts of high-grade mineralisation and boasts a rare combination of high grades and shallow mineralisation starting at surface, supporting an open pit development. “We think, possibly the second highest niobium deposit in terms of grade and, probably one of the highest rare earth deposits,” he told Proactive. He confirmed the company has already seen interest from industry players, with some expressing interest in potential partnerships and even mergers. The resource was released following St George’s acquisition of the project in late February, and the company has committed to a drill program starting in the coming weeks. According to Prineas, this program could potentially double the existing resource. In Brazil, St George has assembled an experienced in-country team and engaged a global EPC contractor to progress mine development. The company has also begun metallurgical and downstream processing studies and believes the project will deliver a commercial-grade product, supported by decades of similar production by neighbours CBMM. 👉 For more interviews like this, visit Proactive's YouTube channel. Don’t forget to like this video, subscribe, and enable notifications so you never miss an update. #StGeorgeMining #Niobium #RareEarths #JORCResource #MiningExploration #ASX #CriticalMinerals #BrazilMining #ResourceUpdate #MineralDiscovery #JohnPrineas #ProactiveInvestors

Proactive - Interviews for investors

Time Finance CEO on Q3 update: record lending & growth to resilient small businesses

Time Finance PLC (AIM:TIME) CEO Ed Rimmer takes Proactive's Stephen Gunnion through the company’s performance in the third quarter, highlighting a record gross lending book and improved arrears management. Rimmer explained that Time Finance provides funding solutions to small businesses, including invoice finance, asset finance, and secured loans, typically supporting businesses with turnover up to £10 million. He said, “We help businesses grow, but we also help businesses to survive as well.” The company’s lending book reached a record £210 million at the end of February, with arrears falling to 5% from 6% a year earlier. Rimmer noted this progress came despite challenging market conditions and was achieved without compromising credit quality. Margins have also increased, with profit margins now at 40%. This was attributed to tight cost control and improved efficiency, including leveraging technology and streamlining internal processes. Time Finance has not increased its headcount significantly post-COVID, which has helped support margin growth. Rimmer also addressed the broader economic environment, pointing to interest rate pressures, inflation, and increased insolvencies, but emphasised that small businesses remain resilient. The company sees opportunity as traditional banks become more risk-averse, creating space for independent lenders. Visit Proactive’s YouTube channel for more interviews like this. Don’t forget to like the video, subscribe to the channel, and enable notifications so you never miss an update. #TimeFinance #SMElending #AlternativeFinance #BusinessLoans #InvoiceFinance #AssetFinance #Q3TradingUpdate #IndependentLender #FinancialResults #SmallBusinessFinance

Followers	416
Posts	52354
Boards Moderated	13
Alias Born	12/16/2001

Volume:	6,554,333
Day Range:	57.52 - 61.05
Bid:	59.00
Ask:	60.00
Last Trade Time:	7:55:52 PM EDT
Total Trades:	96,609

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

DXCM Detailed Quote

Recent DXCM News

More DXCM News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent DXCM News

Go Ad-Free